UBCMJ Volume 9, Issue 1 [5.1 MB]
Britton H., Qiu A.
UBCMJ. 2017: 9.1 (3)
Personalized care for the oncology patient
Lim H.J., Marra M., Laskin J.
UBCMJ. 2017: 9.1 (4-5)
The dark matter of personalized medicine: Non– genetic variation
Coutin N.P.J., Nislow C.
UBCMJ. 2017: 9.1 (6-7)
The promise of personalized medicine: A business–focused perspective
UBCMJ. 2017: 9.1 (8-9)
The emerging role of the microbiome in precision medicine: An overview
UBCMJ. 2017: 9.1 (10-12)
Distinguishing neuromyelitis optica spectrum disorder from multiple sclerosis using magnetic resonance imaging techniques
Lee L.E., Kolind S., Tam R., Carruthers R., Traboulsee A.
UBCMJ. 2017: 9.1 (13-15)
Visual hallucinations in patients receiving intravitreal anti–VEGF agents in northern British Columbia: Prevalence and characteristics
Nguyen M., Hartwig K., Klassen-Ross T., Banner D., Lukaris A.
UBCMJ. 2017: 9.1 (16-18)
From targeted to pinpoint: The implementation of pharmacogenomics in clinical oncology
UBCMJ. 2017: 9.1 (19-20)
Nanotechnology as a platform for personalized cancer therapy
UBCMJ. 2017: 9.1 (21-22)
First, do no harm: The role of cannabis education in response to the opioid crisis
Thiessen M.S., Matthews L., Walsh Z.
UBCMJ. 2017: 9.1 (23-24).
Machine doctor (MD): The threat to human medical doctors’ job security from deep learning
UBCMJ. 2017: 9.1 (25-26).
Meeting the needs of persons with dementia: Challenges facing speech–language pathologists
UBCMJ. 2017: 9.1 (27-28).
Opportunities and challenges in using targeted next–generation sequencing for the diagnosis of dyslipidemias
UBCMJ. 2017: 9.1 (29-30).
NEWS AND LETTERS
Tip–toeing into the world of genomics: Ethics of gene sequencing in clinical medicine
UBCMJ. 2017: 9.1 (31-33)
Genomics and biomarker research in drug development: Overrated, or a revolution to come?
UBCMJ. 2017: 9.1 (34-35)
CRISPR/Cas9: The brave new world of genetic engineering
UBCMJ. 2017: 9.1 (36-37)